Skip to main content
PMC home page
Sarcoma logoLink to Sarcoma
. 2003 Mar;7(1):35–41. doi: 10.1080/1357714031000114165

Bisphosphonate Treatment of Benign Multifocal and Unifocal Osteolytic Tumours of Bone

C L M H Gibbons 1, M Petra 1, R Smith 1, N A Athanasou 1,✉
PMCID: PMC2395513  PMID: 18521367

Abstract

Growth of benign tumours and tumour-like lesions of bone results in osteolysis which may cause pathological fracture. Bisphosphonates are anti-osteolytic agents which have proved effective in the treatment of number of osteolytic conditions. In this study we report the results of treatment with the aminobisphosphonate, pamidronate, of three benign osteolytic tumours of bone, two cases of fibrous dysplasia and one of Langerhans cell histiocytosis. In all three cases there was clinical and radiological improvement following treatment. Radiologically, bone lesions did not exhibit progressive enlargement. Two cases of fibrous dysplasia also showed features suggestive of increased bone formation. These findings indicate that bisphosphonates are likely to be useful in controlling the osteolysis of benign tumours/tumour-like lesions of bone, particularly in those cases where surgical intervention is not possible or multifocal lesions are present.

Full Text

The Full Text of this article is available as a PDF (204.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abildgaard N., Rungby J., Glerup H., Brixen K., Kassem M., Brincker H., Heickendorff L., Eriksen E. F., Nielsen J. L. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol. 1998 Aug;61(2):128–134. doi: 10.1111/j.1600-0609.1998.tb01073.x. [DOI] [PubMed] [Google Scholar]
  2. Chapurlat R. D., Delmas P. D., Liens D., Meunier P. J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997 Oct;12(10):1746–1752. doi: 10.1359/jbmr.1997.12.10.1746. [DOI] [PubMed] [Google Scholar]
  3. Elomaa I., Blomqvist C., Porkka L., Holmström T. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone. J Intern Med. 1989 Jan;225(1):59–61. doi: 10.1111/j.1365-2796.1989.tb00038.x. [DOI] [PubMed] [Google Scholar]
  4. Enneking W. F. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986 Mar;(204):9–24. [PubMed] [Google Scholar]
  5. Farran R. P., Zaretski E., Egeler R. M. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol. 2001 Jan;23(1):54–56. doi: 10.1097/00043426-200101000-00013. [DOI] [PubMed] [Google Scholar]
  6. Flanagan A. M., Nui B., Tinkler S. M., Horton M. A., Williams D. M., Chambers T. J. The multinucleate cells in giant cell granulomas of the jaw are osteoclasts. Cancer. 1988 Sep 15;62(6):1139–1145. doi: 10.1002/1097-0142(19880915)62:6<1139::aid-cncr2820620617>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  7. Fleisch H. Can bisphosphonates be given to patients with fractures? J Bone Miner Res. 2001 Mar;16(3):437–440. doi: 10.1359/jbmr.2001.16.3.437. [DOI] [PubMed] [Google Scholar]
  8. HARRIS W. H., DUDLEY H. R., Jr, BARRY R. J. The natural history of fibrous dysplasia. An orthopaedic, pathological, and roentgenographic study. J Bone Joint Surg Am. 1962 Mar;44-A:207–233. [PubMed] [Google Scholar]
  9. Harris M. Central giant cell granulomas of the jaws regress with calcitonin therapy. Br J Oral Maxillofac Surg. 1993 Apr;31(2):89–94. doi: 10.1016/0266-4356(93)90168-v. [DOI] [PubMed] [Google Scholar]
  10. Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995 Oct;10(10):1478–1487. doi: 10.1002/jbmr.5650101008. [DOI] [PubMed] [Google Scholar]
  11. Lane J. M., Khan S. N., O'Connor W. J., Nydick M., Hommen J. P., Schneider R., Tomin E., Brand J., Curtin J. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res. 2001 Jan;(382):6–12. doi: 10.1097/00003086-200101000-00003. [DOI] [PubMed] [Google Scholar]
  12. Liens D., Delmas P. D., Meunier P. J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994 Apr 16;343(8903):953–954. doi: 10.1016/s0140-6736(94)90069-8. [DOI] [PubMed] [Google Scholar]
  13. Lin J. H. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb;18(2):75–85. doi: 10.1016/8756-3282(95)00445-9. [DOI] [PubMed] [Google Scholar]
  14. Nishikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugal N., Yamamoto M., Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 1996 Jan;18(1):9–14. doi: 10.1016/8756-3282(95)00426-2. [DOI] [PubMed] [Google Scholar]
  15. Rogers M. J., Gordon S., Benford H. L., Coxon F. P., Luckman S. P., Monkkonen J., Frith J. C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000 Jun 15;88(12 Suppl):2961–2978. doi: 10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c. [DOI] [PubMed] [Google Scholar]
  16. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 1990 Jan;5(1):31–40. doi: 10.1002/jbmr.5650050107. [DOI] [PubMed] [Google Scholar]
  17. Sauty A., Pecherstorfer M., Zimmer-Roth I., Fioroni P., Juillerat L., Markert M., Ludwig H., Leuenberger P., Burckhardt P., Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996 Feb;18(2):133–139. doi: 10.1016/8756-3282(95)00448-3. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES